Peregrine upbeat on Phase II bavituximab breast cancer survival data
This article was originally published in Scrip
Executive Summary
Peregrine Pharmaceuticals has reported promising survival data from a Phase II advanced breast cancer trial for its first-in-class phosphatidylserine inhibitor, bavituximab, a result that the company says supports the ongoing development of the drug in lung cancer and other indications.